RANCHO CORDOVA, Calif., April 03, 2017 (GLOBE NEWSWIRE) — Cesca Therapeutics Inc. (Nasdaq:KOOL), a market leader in automated cell processing and point-of-care, autologous cell-based therapies, today announced the following senior management promotions, effective immediately.
- Ms. Haihong Zhu, who most recently served as Director of Sales, has been promoted to the newly-created position of General Manager of ThermoGenesis, Cesca’s device division. Ms. Zhu has been with Cesca since 2004, serving in various technical and sales positions, and contributed significantly to the establishment of Cesca’s commercial presence in China.
- Dr. Dalip Sethi, who has served as Director of Clinical Research (USA), has been promoted to the position of Senior Director of Research and Development. Dr. Sethi, who has been with the Company since 2012, will spearhead Cesca’s clinical development of novel cell therapy methods for treating vascular and orthopedic diseases.
- Mr. Jeff Cauble, most recently holding the position of Director of Finance, has been promoted to the position of Principal Accounting Officer. Mr. Cauble has been with Cesca since 2010 and has served in various accounting management positions of increasing responsibility.
“These senior team members have contributed greatly to our success in developing and commercializing our proprietary cell-based therapies and devices, and I am delighted to recognize their ongoing leadership and commitment to the company through these promotions,” said Chris Xu, interim Chief Executive Officer of Cesca. “We are fortunate at Cesca to have a deep and seasoned management team, and with these key individuals assuming expanded roles, we believe we have the team in place to successfully shepherd Cesca Therapeutics through its next phase of growth.”
About Cesca Therapeutics Inc.
About Cesca (www.cescatherapeutics.com): Cesca is engaged in the research, development, and commercialization of cellular therapies and delivery systems for use in regenerative medicine. The Company is a leader in the development and manufacture of automated blood and bone marrow processing systems that enable the separation, processing and preservation of cell and tissue therapeutics.
The statements contained herein may include statements of future expectations and other forward-looking statements that are based on management’s current views and assumptions and involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. A more complete description of risks that could cause actual events to differ from the outcomes predicted by Cesca Therapeutics’ forward-looking statements is set forth under the caption “Risk Factors” in Cesca Therapeutics annual report on Form 10-K and other reports it files with the Securities and Exchange Commission from time to time, and you should consider each of those factors when evaluating the forward-looking statements.
Investor Contact: Rx Communications Paula Schwartz 917-322-2216 firstname.lastname@example.org